前收市價 | 0.7400 |
開市 | 0.7400 |
買盤 | 0.0000 x 0 |
賣出價 | 0.0000 x 0 |
今日波幅 | 0.7300 - 0.7600 |
52 週波幅 | 0.7300 - 12.8000 |
成交量 | |
平均成交量 | 66,459 |
市值 | 2.177M |
Beta 值 (5 年,每月) | 1.12 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -12.0000 |
業績公佈日 | 2024年4月08日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 4.30 |
Monday, Biophytis SA (NASDAQ:BPTS) announced the launch of a new clinical development program named OBA, with BIO101 (20-hydroxyecdysone) as a potential treatment for obesity combined with GLP-1 receptor agonists. The OBA Phase 2 clinical study is expected to start in mid-2024, upon regulatory approvals, with the first patients expected to be treated in the second half of 2024. BIO101 (20-hydroxyecdysone) will be evaluated in obese patients treated with GLP-1 RAs and following hypocaloric dietin
Biophytis (BPTS) rises in the after-market hours as it announces the launch of a new clinical development program for its investigational candidate, BIO101, to treat obesity in combination with GLP-1 drugs.
In this article, we look at 40 cities with the lowest life expectancy in the US. You can skip our section on developments in the pharmaceutical and biotech industries to enhance longevity and head over directly to 10 Cities with the Lowest Life Expectancy in the US. Average lifespan in the US climbed from just […]